Tislelizumab+liposomal doxorubicin+ifosfamide
4 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| Tislelizumab+liposomal doxorubicin+ifosfamide for desmoplastic small round cell tumor | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tislelizumab+liposomal doxorubicin+ifosfamide for hemangiosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tislelizumab+liposomal doxorubicin+ifosfamide for leiomyosarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tislelizumab+liposomal doxorubicin+ifosfamide for liposarcoma | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |